On August 21, Gilead Sciences rose 3.07% in regular trading, trading at $147.85 per share, with turnover of $228 million. The stock has maintained upward momentum since the company announced a major acquisition earlier this week.

On August 18, Gilead Sciences announced the acquisition of cancer therapy developer Arcellx at an equity value of $7.8 billion, offering $115 per share in cash plus $5 per share in contingent value rights, representing an 87% premium to Arcellx's prior closing price. The market views this as a significant strategic move to further strengthen Gilead's oncology pipeline, and the deal has continued to buoy investor sentiment since its announcement.

Adding to the positive momentum, Gilead's Q2 results reported on August 4 showed revenue of $7.8 billion, exceeding the $7.4 billion analyst consensus. Full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, meaningfully better than the FactSet estimate of $0.75 loss. The company also raised its full-year HIV business growth outlook to 9%-10%, up from the prior 8% guidance, reflecting continued operational strength in its core franchise.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)